Literature DB >> 22908200

A brain on cannabinoids: the role of dopamine release in reward seeking.

Erik B Oleson1, Joseph F Cheer.   

Abstract

Increases in mesolimbic dopamine transmission are observed when animals are treated with all known drugs of abuse, including cannabis, and to conditioned stimuli predicting their availability. In contrast, decreases in mesolimbic dopamine function are observed during drug withdrawal, including cannabis-withdrawal syndrome. Thus, despite general misconceptions that cannabis is unique from other drugs of abuse, cannabis exerts identical effects on the mesolimbic dopamine system. The recent discovery that endogenous cannabinoids modulate the mesolimbic dopamine system, however, might be exploited for the development of potential pharmacotherapies designed to treat disorders of motivation. Indeed, disrupting endocannabinoid signaling decreases drug-induced increases in dopamine release in addition to dopamine concentrations evoked by conditioned stimuli during reward seeking.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22908200      PMCID: PMC3405830          DOI: 10.1101/cshperspect.a012229

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  82 in total

Review 1.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia.

Authors:  A A Grace
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

2.  THC does not affect striatal dopamine release: microdialysis in freely moving rats.

Authors:  E Castañeda; D E Moss; S D Oddie; I Q Whishaw
Journal:  Pharmacol Biochem Behav       Date:  1991-11       Impact factor: 3.533

3.  Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.

Authors:  M Herkenham; A B Lynn; B R de Costa; E K Richfield
Journal:  Brain Res       Date:  1991-05-03       Impact factor: 3.252

4.  Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis.

Authors:  J P Chen; W Paredes; J Li; D Smith; J Lowinson; E L Gardner
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient.

Authors:  J Chen; R Marmur; A Pulles; W Paredes; E L Gardner
Journal:  Brain Res       Date:  1993-09-03       Impact factor: 3.252

6.  Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study.

Authors:  J P Chen; W Paredes; J H Lowinson; E L Gardner
Journal:  Neurosci Lett       Date:  1991-08-05       Impact factor: 3.046

Review 7.  Marijuana's interaction with brain reward systems: update 1991.

Authors:  E L Gardner; J H Lowinson
Journal:  Pharmacol Biochem Behav       Date:  1991-11       Impact factor: 3.533

8.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors:  W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

9.  Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration.

Authors:  F Weiss; A Markou; M T Lorang; G F Koob
Journal:  Brain Res       Date:  1992-10-16       Impact factor: 3.252

10.  Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats.

Authors:  Z L Rossetti; Y Hmaidan; G L Gessa
Journal:  Eur J Pharmacol       Date:  1992-10-20       Impact factor: 4.432

View more
  44 in total

1.  Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Authors:  Jason M Wiebelhaus; Travis W Grim; Robert A Owens; Matthew F Lazenka; Laura J Sim-Selley; Rehab A Abdullah; Micah J Niphakis; Robert E Vann; Benjamin F Cravatt; Jenny L Wiley; S Stevens Negus; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2014-11-14       Impact factor: 4.030

2.  Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell.

Authors:  Sheketha R Hauser; Simon N Katner; Robert A Waeiss; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2020-07-23       Impact factor: 3.533

3.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

Review 4.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

Review 5.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

Review 6.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

Review 7.  Commonalities and Distinctions Among Mechanisms of Addiction to Alcohol and Other Drugs.

Authors:  Angela R Ozburn; Aaron J Janowsky; John C Crabbe
Journal:  Alcohol Clin Exp Res       Date:  2015-10       Impact factor: 3.455

Review 8.  Illicit dopamine transients: reconciling actions of abused drugs.

Authors:  Dan P Covey; Mitchell F Roitman; Paul A Garris
Journal:  Trends Neurosci       Date:  2014-03-20       Impact factor: 13.837

Review 9.  Endogenous cannabinoid signaling at inhibitory interneurons.

Authors:  Thomas J Younts; Pablo E Castillo
Journal:  Curr Opin Neurobiol       Date:  2013-12-28       Impact factor: 6.627

10.  Differential Control of Cocaine Self-Administration by GABAergic and Glutamatergic CB1 Cannabinoid Receptors.

Authors:  Elena Martín-García; Lucie Bourgoin; Adeline Cathala; Fernando Kasanetz; Miguel Mondesir; Ana Gutiérrez-Rodriguez; Leire Reguero; Jean-François Fiancette; Pedro Grandes; Umberto Spampinato; Rafael Maldonado; Pier Vincenzo Piazza; Giovanni Marsicano; Véronique Deroche-Gamonet
Journal:  Neuropsychopharmacology       Date:  2015-11-27       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.